Fexagratinib (** Pemazyre (Generic: pemigatinib) **)

Targeted Therapy

EU Experimental ES Not available 1 Clinical Trials

Description

Fexagratinib (brand name Pemazyre) is a targeted therapy drug. It is currently being studied in clinical trials for certain types of cancer, including colorectal cancer, specifically in patients whose tumors have a MET mutation. It is not yet approved for treating colorectal cancer. Clinical trials are investigating its effectiveness in patients with advanced or refractory solid tumors, including colorectal cancer, where specific genetic changes (like MET mutations) are present. The goal is to see if targeting these specific changes can help control or shrink the cancer. It is being tested in combination with other drugs as well.

Mechanism of Action

Fexagratinib targets a specific protein involved in cell signaling pathways that can drive tumor growth. In cancers with MET mutations, this protein may be overactive, contributing to cancer progression. Fexagratinib works by blocking the activity of this protein, potentially slowing or stopping cancer cell growth and spread. The specific protein targeted by fexagratinib is MET.

Side Effects

As fexagratinib is still being studied in clinical trials for colorectal cancer The full range of side effects is still being evaluated. Common side effects observed in trials for other cancers include fatigue Diarrhea Nausea Vomiting Decreased appetite Constipation And abdominal pain. More serious side effects can occur Such as bleeding Blood clots And heart problems. Patients participating in clinical trials are closely monitored for side effects.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02465060 Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
United States, Guam, Puerto Rico

Quick Info

Brand Name** Pemazyre (Generic: pemigatinib) **
CategoryTargeted Therapy
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Regorafenib
Targeted Therapy
109 trials
Rego
Targeted Therapy
109 trials
Fruquintinib
Targeted Therapy
59 trials
Encorafenib
Targeted Therapy
26 trials
Binimetinib
Targeted Therapy
22 trials
Trametinib
Targeted Therapy
22 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.